Lipodox 20mg Injection

Lipodox 20mg Injection is a chemotherapy based anti-cancer medication. It contains Doxorubicin Lliposomal as its active ingredient. Doctor prescribes it to treat certain types of cancer such as bladder cancer, breast cancer, lung cancer, stomach cancer, ovarian cancer, leukemia cancer, and AIDS-related Kaposi’s sarcoma.

It works by interfering with the growth and multiplication of cancer cells to slow down the progression of cancer. It is administered intravenously (into a vein) by a qualified healthcare professional in a hospital or clinic setting. It is not for self-administration.​

• Breast cancer
• Ovarian cancer
• Bladder cancer
• Lung  cancer
• Stomach cancer
• Multiple myeloma
• AIDS-related Kaposi’s sarcoma

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Lipodox 20mg Injection  can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Low blood cell counts
• Hair loss
• Decreased appetite
• Skin rashes
• Pain in the muscles and joints
• Constipation
• Feeling confused, difficulty sleeping
• Headache, dizziness, sleepiness
• Change in taste
• High or low blood pressure
• Excessive sweating
• Pain when passing urine
• Weight loss
• Muscle spasms
• Fast heartbeat

Seek medical attention in case of any unusual or severe side effects immediately

• Lipodox 20mg Injection is a powerful anticancer medicine that can only be given intravenously by a doctor or nurse under strict medical supervision.
• It is not self-administerable. Dosage and duration of the treatment are determined by the doctor as per the patient's health condition and type & stage of the cancer.​​
  

• Lipodox 20mg Injection is a chemotherapy based anti-cancer medication. It contains Doxorubicin Lliposomal as its active ingredient.
• It works by inhibits the activity of the enzyme topoisomerase II, which is involved in the DNA (genetic material) multiplication of cancer cells to slow down the progression of cancer. Thereby prevent the growth & multiplication of abnormal cells.​
  

• Patel, J. (1996). Liposomal doxorubicin: Doxil®. Journal of Oncology Pharmacy Practice, 2(4), 201-210.
• Hilmer, S. N., Cogger, V. C., Muller, M., & Le Couteur, D. G. (2004). The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug metabolism and disposition, 32(8), 794-799.
• Lao, J., Madani, J., Puértolas, T., Álvarez, M., Hernández, A., Pazo-Cid, R., ... & Antón Torres, A. (2013). Liposomal doxorubicin in the treatment of breast cancer patients: a review. Journal of drug delivery, 2013(1), 456409.
• Niu, G., Cogburn, B., & Hughes, J. (2010). Preparation and characterization of doxorubicin liposomes. In Cancer nanotechnology: methods and protocols (pp. 211-219). Totowa, NJ: Humana Press.
• Chowdhury, N., Chaudhry, S., Hall, N., Olverson, G., Zhang, Q. J., Mandal, T., ... & Kundu, A. (2020). Targeted delivery of doxorubicin liposomes for Her-2+ breast cancer treatment. Aaps Pharmscitech, 21(6), 202.
• Tardi, P., Boman, N., & Cullis, P. (1996). Liposomal doxorubicin. Journal of drug targeting, 4(3), 129-140.